

---

**A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.**

**Alpha Trial Link:**

<https://clinicaltrials.gov/ct2/show/NCT01567891?term=AdaptImmune+AND+ovarian+cancer&rank=1>

**Alpha Clinic (primary):**

City of Hope

**Contact:**

**Name:**

Mihaela Cristea, MD

**Phone:**

(626) 256-4673 x89200

**Email:**

[mcristea@coh.org](mailto:mcristea@coh.org)

---

**Alpha Trial Sponsor:**

Adaptimmune

**Disease Indication:**

Cancer - Ovarian

**Enrollment Status:**

Recruiting

---

**Source URL:** <https://www.cirm.ca.gov/alphaclinictrial/phase-iiia-open-label-clinical-trial-evaluating-safety-and-efficacy-autologous-t>